← back to search

Patricio O’Donnell

Sage Therapeutics (United States) · US
Area of research
Cellular and Molecular Neuroscience · Cognitive Neuroscience
Research interest
Research interests include Neuroscience and Neuropharmacology Research, Neurotransmitter Receptor Influence on Behavior, Neural dynamics and brain function, and Memory and Neural Mechanisms.
h-index
60
citations
13,353
works
203
NIH funding
primary concept
email

Recent publications

Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study
npj Parkinson s Disease 2023cited by 89position: middledoi
Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group
Molecular Psychiatry 2017cited by 724position: middledoi
Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia
Molecular Psychiatry 2017cited by 358position: middledoi
Translating genome-wide association findings into new therapeutics for psychiatry
Nature Neuroscience 2016cited by 130position: middledoi
Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets
Nature Reviews Drug Discovery 2016cited by 80position: middledoi
Nucleus Accumbens Medium Spiny Neuron Subtypes Mediate Depression-Related Outcomes to Social Defeat Stress
Biological Psychiatry 2014cited by 381position: middledoi
Early Social Experience Is Critical for the Development of Cognitive Control and Dopamine Modulation of Prefrontal Cortex Function
Neuropsychopharmacology 2013cited by 212position: middledoi
Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy
Proceedings of the National Academy of Sciences 2012cited by 146position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 2 papers (2016–2017)Paul F. O’Reilly · Icahn School of Medicine at Mount Sinai1 papers (2016–2016) · 1 papers (2016–2016)Ramesh Chandra · University of Maryland, Baltimore1 papers (2014–2014) · 1 papers (2016–2016)Mark A. Geyer · Multidisciplinary Association for Psychedelic Studies1 papers (2016–2016) · 1 papers (2016–2016)Louk J. M. J. Vanderschuren · Utrecht University1 papers (2013–2013)Genesis Dayrit · University of Maryland, Baltimore1 papers (2014–2014)Shitij Kapur · University of Sheffield1 papers (2016–2016)Thomas Steckler · Johnson & Johnson (Brazil)1 papers (2016–2016)Mark J. Millan · AVL (France)1 papers (2016–2016)Qingqin S. Li · Virginia Commonwealth University1 papers (2016–2016)Daniel R. Weinberger · Johns Hopkins University1 papers (2012–2012)Ricardo E. Dolmetsch · Amsterdam UMC Location Vrije Universiteit Amsterdam1 papers (2016–2016)Howard J. Edenberg · University of Iowa1 papers (2016–2016) · 1 papers (2016–2016) · 1 papers (2017–2017)Paul J. Harrison · Deakin University1 papers (2012–2012)Daniëlle Posthuma · Icahn School of Medicine at Mount Sinai1 papers (2016–2016)